نتائج البحث - Gerjo A. Velders
- يعرض 1 - 2 نتائج من 2
-
1
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment حسب Iris de Weerdt, Tom Hofland, Renate de Boer, Johan A. Dobber, Julie Dubois, Denise van Nieuwenhuize, Mehrdad Mobasher, Fransien de Boer, Mels Hoogendoorn, Gerjo A. Velders, Marjolein van der Klift, Ester B. M. Remmerswaal, Fréderike J. Bemelman, Carsten Utoft Niemann, Sabina Kersting, Mark‐David Levin, Eric Eldering, Sanne H. Tonino, Arnon P. Kater
منشور في 2019Artigo -
2
Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a m... حسب Sabina Kersting, Julie Dubois, Kazem Nasserinejad, Johan A. Dobber, Clemens Mellink, Anne-Marie Van Der Kevie-Kersemaekers, Ludo M. Evers, Fransien de Boer, Harry R. Koene, John Schreurs, Marjolein van der Klift, Gerjo A. Velders, Ellen van der Spek, Hanneke M. Straaten, Mels Hoogendoorn, Michel van Gelder, Eduardus F. M. Posthuma, Hein P. J. Visser, Ilse Houtenbos, Cecile Idink, Djamila E. Issa, Ellen C. Dompeling, H.C.T. van Zaanen, Hendrik Veelken, Henriëtte Levenga, Lidwine W. Tick, Wim Terpstra, Sanne H. Tonino, Michelle Boyer, Mehrdad Mobasher, Mark‐David Levin, Arnon P. Kater
منشور في 2022Artigo
أدوات البحث:
موضوعات ذات صلة
Chronic lymphocytic leukemia
Internal medicine
Leukemia
Medicine
Oncology
Venetoclax
Chemotherapy
Clinical endpoint
Cyclophosphamide
Fludarabine
Immune system
Immunology
Lymph
Lymph node
Minimal residual disease
Obinutuzumab
Pathology
Peripheral
Peripheral blood
Progressive disease
Randomized controlled trial
Surgery